Johns Hopkins Hospital Joins Precision Biologics as a Collaborator on Phase 2A Pancreatic and Colorectal Cancer Trial
Press:Precision BiologicsSophia Lall(o) 212-414-1909(c) 718-483-0735
Precision Biologics is pleased to announce the addition of Johns Hopkins Hospital as a collaborator on its ongoing Phase 2a clinical trial with its lead therapeutic compound NPC-1C (NEO-102). NPC-1C was highlighted on the cover of the of the journal “Cancer Immunology, Immunotherapy (Springer)” and provides a detailed and in depth description of the discovery and development of this novel compound (see link below). In addition, encouraging clinical results of more than doubling of survival rates of pancreatic cancer and prolongation of survival of colorectal cancer patients were presented at the 2013 ASCO Annual meeting.
The addition of Johns Hopkins will parallel and compliment patient enrollment currently underway at both Duke University Medical Center and the University of Texas Southwestern (UTSW). This ongoing study is currently treating patients with the monoclonal antibody NPC-1C that targets a variant MUC-5ac that is expressed in the tumor of patients with pancreatic and colorectal cancer. The study will enroll patients with advanced disease who have been refractory to conventional therapy for these cancers. Dr. Philip M. Arlen, CEO and Chief Medical Officer of Precision Biologics, said, “we look forward to fostering our relationship with the investigators at Johns Hopkins for future therapeutic development, and we are encouraged that this collaboration will lead to accelerated patient enrollment with an opportunity for improved outcomes at optimized therapeutic doses of NPC-1C.”
Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials.
2013 ASCO Annual Meeting presentation: